Nextgen (NXGN) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.111x

Based on the latest financial reports, Nextgen (NXGN) has a cash flow conversion efficiency ratio of 0.111x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.08 Million ≈ $-2.90K USD) by net assets (ILA-9.72 Million ≈ $-26.05K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Nextgen - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Nextgen's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Nextgen (NXGN) total liabilities for a breakdown of total debt and financial obligations.

Nextgen Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nextgen ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Ngenic AB
ST:NGENIC
0.592x
GGX Gold Corp
V:GGX
0.054x
GEMINA LABS LTD
F:8I7
-0.007x
CanadaBis Capital Inc
V:CANB
0.056x
CBEYOND
F:C5B
-0.187x
Pineapple Financial Inc.
NYSE:PAPL
0.471x
Im Cannabis Corp
NASDAQ:IMCC
-1.169x
Creative Eye Limited
NSE:CREATIVEYE
-0.060x

Annual Cash Flow Conversion Efficiency for Nextgen (2013–2024)

The table below shows the annual cash flow conversion efficiency of Nextgen from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Nextgen worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ILA-2.46 Million
≈ $-6.61K
ILA-2.06 Million
≈ $-5.53K
0.837x -81.41%
2023-12-31 ILA-979.00K
≈ $-2.62K
ILA-4.41 Million
≈ $-11.81K
4.499x +2102.13%
2022-12-31 ILA12.25 Million
≈ $32.84K
ILA-2.75 Million
≈ $-7.38K
-0.225x -75.07%
2021-12-31 ILA20.71 Million
≈ $55.51K
ILA-2.66 Million
≈ $-7.13K
-0.128x +42.64%
2020-12-31 ILA6.87 Million
≈ $18.41K
ILA-1.54 Million
≈ $-4.12K
-0.224x +77.11%
2019-12-31 ILA1.17 Million
≈ $3.14K
ILA-1.15 Million
≈ $-3.07K
-0.978x -88.16%
2018-12-31 ILA2.39 Million
≈ $6.40K
ILA-1.24 Million
≈ $-3.33K
-0.520x -14.45%
2017-12-31 ILA3.66 Million
≈ $9.81K
ILA-1.66 Million
≈ $-4.45K
-0.454x -54.05%
2016-12-31 ILA5.13 Million
≈ $13.76K
ILA-1.51 Million
≈ $-4.06K
-0.295x +87.25%
2015-12-31 ILA1.74 Million
≈ $4.65K
ILA-4.01 Million
≈ $-10.76K
-2.312x -162.46%
2014-12-31 ILA-884.00K
≈ $-2.37K
ILA-3.27 Million
≈ $-8.77K
3.702x +205.08%
2013-12-31 ILA342.00K
≈ $916.89
ILA-1.21 Million
≈ $-3.23K
-3.523x --

About Nextgen

TA:NXGN Israel Medical Instruments & Supplies
Market Cap
$1.53 Million
ILA569.04 Million ILA
Market Cap Rank
#29915 Global
#442 in Israel
Share Price
ILA52.20
Change (1 day)
+0.00%
52-Week Range
ILA37.60 - ILA70.00
All Time High
ILA25020.00
About

Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.